Related Experiment Videos
Selective estrogen receptor modulators prevent neointima formation after vascular injury
Hanna Savolainen-Peltonen1, Nina-Maria Luoto, Lauri Kangas
1Rational Drug Design Programme, Transplantation Laboratory, Helsinki University Central Hospital, P. O. Box 63, Helsinki, Finland. Hanna.Peltonen@Helsinki.Fi
Molecular and Cellular Endocrinology
|October 27, 2004
Summary
Selective estrogen receptor modulators (SERMs) show promise for vascular health by reducing neointimal thickening and improving reendothelialization after injury. These compounds offer therapeutic potential without the adverse effects of estrogen on reproductive tissues.
Area of Science:
- Cardiovascular Pharmacology
- Endocrinology
- Vascular Biology
Background:
- Estrogen possesses vasculoprotective effects, but its clinical use is limited by adverse effects on the endometrium and breast.
- Selective Estrogen Receptor Modulators (SERMs) offer tissue-specific estrogenic or anti-estrogenic activity, presenting a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy of tamoxifen, raloxifene, ospemifene, and fispemifene in preserving estrogen's beneficial vascular effects in an ovariectomized rat model.
- To compare SERM efficacy with 17beta-estradiol (17beta-E2) and the pure anti-estrogen ICI 182,780 in mitigating vascular injury responses.
Main Methods:
- Ovariectomized rats underwent aorta denudation injury, followed by treatment with various doses of SERMs, 17beta-E2, or ICI 182,780.
- Neointimal thickening, nuclei number, intimal area, and reendothelialization were assessed at 7 and 28 days post-injury.
- In vitro studies evaluated the effects of compounds on vascular smooth muscle cell (SMC) replication and migration.
Main Results:
- All tested compounds dose-dependently inhibited neointimal thickening at 7 days.
- Tamoxifen and ospemifene significantly reduced intimal area and nuclei number at 28 days, comparable to 17beta-E2.
- SERMs enhanced reendothelialization and inhibited SMC proliferation and migration in vitro; 17beta-E2 uniquely increased uterine weight.
Conclusions:
- SERMs demonstrate estrogen-like agonist effects in the injured vascular wall, regulating SMC function and promoting reendothelialization.
- Early intervention with SERMs is crucial for preventing the vascular injury response.
- SERMs represent a promising therapeutic avenue for vascular protection, potentially avoiding estrogen's systemic side effects.